ETON — Eton Pharmaceuticals Inc
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
$61.64
+$1.21 (+2.00%)
Eton Pharmaceuticals Inc (ETON) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Sean E. Brynjelsen, based in 21925 W. Field Parkway, Deer Park, IL, United States, 60010-7278, with about 44 employees. Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Latest reported ETON revenue for 2025-09-30 was $22.5M. Net income was -$1.9M. Revenue was up 18.7% from 2025-06-30 to 2025-09-30. ETON currently screens at market cap $797.9M.
Use this ETON page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ETON quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ETON SEC filings page. Lician reads the product cache first so this HTML stays unique to Eton Pharmaceuticals Inc even when a live quote feed is slow.
About Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
ETON Key Statistics
Market Cap
$797.94M
Volume
534,072
Previous Close
$64.43
Day Range
$62.00 – $65.50
EPS
$0.00
Revenue
$39.01M
Net Income
-$3.82M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+23.3%
Profit Margin
-9.8%
Employees
44
ETON Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $39.01M | $31.64M | $21.25M | $21.83M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$3.82M | -$936.00K | -$9.02M | -$1.96M |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 |
Total Assets
$76.12M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$14.94M
Operating Cash Flow
$969.00K
Free Cash Flow
$0.00
Eton Pharmaceuticals Inc Company Information
- President, CEO & Director
- Sean E. Brynjelsen
- Headquarters
- 21925 W. Field Parkway, Deer Park, IL, United States, 60010-7278
- Website
- www.etonpharma.com
- Phone
- 847 787 7361
- IPO / Founded
- 2018-11-13
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic